[ad_1]
SCYNEXIS Inc.
SCYNEXIS, Inc. is a biotechnology company engaged in the advancement of novel oral and intravenous triterpenoid antifungal for the procedure of various significant fungal bacterial infections, like vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal bacterial infections. The firm was launched by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
[ad_2]
Supply hyperlink